Evidence map›Paper›PMID 34386018›Full record

ArticleFrontiers in immunology2021

HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine.

Concetta Ragone, Serena Meola, Pasqualina C Fiorillo, Roberta Penta, Laura Auriemma, Maria Lina Tornesello, Leonardo Miscio, Ernesta Cavalcanti, Gerardo Botti, Franco M Buonaguro and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. An overview of HLA variants in COVID-19 vaccine-induced autoimmunity.International journal of molecular epidemiology and genetics · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Associations ofVaccines · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Concetta RagoneInnovative Immunological Models Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Serena MeolaLaboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Pasqualina C FiorilloLaboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Roberta PentaBa.S.C.O. Unit, Cellular Manipulation and Immunogenetics, Oncology Department, AORN Santobono-Pausilipon, Naples, Italy.
Laura AuriemmaBa.S.C.O. Unit, Cellular Manipulation and Immunogenetics, Oncology Department, AORN Santobono-Pausilipon, Naples, Italy.
Maria Lina TorneselloMolecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Leonardo MiscioMedical Direction, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Ernesta CavalcantiLaboratory Medicine Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Gerardo BottiScientific Direction, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Franco M BuonaguroMolecular Biology and Viral Oncogenesis Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Attilio BianchiGeneral Direction, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Luigi BuonaguroInnovative Immunological Models Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Maria TagliamonteInnovative Immunological Models Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione Pascale"-IRCCS, Naples, Italy.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The response to anti-SARS-Cov-2 preventive vaccine shows high interpersonal variability at short and medium term. One of the explanations might be the individual HLA allelic variants. Indeed, B cell response is stimulated and sustained by CD4

Indexed as

Antibodies, ViralAntibody AffinityAntigens, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesHLA-D AntigensHumansSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralAntigens, ViralBNT162 VaccineCOVID-19 VaccinesHLA-D AntigensSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibody titer levelBNT162b2 mRNA COVID-19 vaccineHLA-DQ antigensHLA-DR antigensSARS-CoV-2

Identifiers

PMID34386018
PMCPMC8353253
OpenAlexW3186368744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.